MORRISVILLE, N.C., Aug. 07, 2017 -- Clinipace Worldwide, a global full-service clinical research organization (CRO), has appointed Nikolas Burlew as Executive Vice President, RSD Global Consulting. Burlew will head up Clinipace’s newly launched RSD Global Consulting Group (RSDGC), providing strategic consulting and regulatory support in the United States, Europe, and Asia Pacific. Clinipace RSDGC provides stage-specific solutions for all phases of development, from non-clinical and clinical, through to marketing applications and post-marketing support.
Burlew – who has been in senior leadership positions within the Regulatory and Strategic Development Group at Clinipace since March 2011 – has 25+ years of experience in drug development, manufacturing and quality assurance. In his new role, he will oversee all elements of the RSD Global Consulting Group, including strategy, finances, business development and human resources.
“I am excited to launch this new consulting offering, which I believe will meet customer needs as part of our full-service approach,” said Nikolas Burlew, who was recently appointed Executive Vice President, RSD Global Consulting, at Clinipace. “Our strategic and regulatory support can reduce development timelines by ensuring that sound decisions are made at every step.”
“Warmest congratulations to Nikolas Burlew on this well-deserved promotion,” said Clinipace President and CEO Jeff Williams. “Nikolas’ depth of experience will drive this new offering, ensuring that Clinipace continues to be the careful steward of our clients’ therapeutic programs, managing costs, quality, and deliverables to help ensure each organization’s goals are met.”
Prior to joining Clinipace, Burlew held positions with Regulus Pharmaceutical Consulting, Sandoz, NaPro BioTherapeutics, and Synergen. He has a BA in Biology from the University of Colorado Boulder.
About Clinipace Worldwide
Clinipace Worldwide, a global full-service clinical research organization (CRO) serves the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms, helping them advance drug candidates to deliver successful stakeholder and patient outcomes. The company leverages extensive therapeutic knowledge, clinical trial expertise, and their proprietary eClinical platform TEMPO™ to support life science firms in achieving some of their most important goals: Executing regulatory strategies, optimizing clinical development timelines and completing high quality trials.
Clinipace has completed more than 1,500 clinical trials and 1,500 regulatory and statistical consulting projects and operates in North America, South American, Europe, and Asia. To learn more, visit www.clinipace.com
Media Contact Sandra Parrish Woodlief 919-797-9480; [email protected]


U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 



